Developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system

Voyager Therapeutics (NASDAQ: VYGR) is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.

Year Invested: 2014
Location: Cambridge, Mass.

Recent News

April 15, 2019
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

April 3, 2019
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)

April 2, 2019
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Read More News

Associated Team Members

Mark Levin

Philip Reilly, M.D., J.D.
Venture Partner